News stories about Paratek Pharmaceuticals (NASDAQ:PRTK) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Paratek Pharmaceuticals earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave media headlines about the specialty pharmaceutical company an impact score of 47.7292997349654 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Paratek Pharmaceuticals, Inc. to Post Q3 2017 Earnings of ($0.87) Per Share, Wedbush Forecasts (NASDAQ:PRTK) (americanbankingnews.com)
- FY2017 Earnings Estimate for Paratek Pharmaceuticals, Inc. (PRTK) Issued By Gabelli (americanbankingnews.com)
- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Upgraded at Zacks Investment Research (americanbankingnews.com)
- BidaskClub Lowers Paratek Pharmaceuticals, Inc. (PRTK) to Hold (americanbankingnews.com)
- Brokers Set Expectations for Paratek Pharmaceuticals, Inc.’s Q3 2017 Earnings (NASDAQ:PRTK) (americanbankingnews.com)
PRTK has been the topic of several recent research reports. Zacks Investment Research raised shares of Paratek Pharmaceuticals from a “hold” rating to a “buy” rating and set a $24.00 price objective on the stock in a report on Thursday, April 20th. HC Wainwright upped their price objective on shares of Paratek Pharmaceuticals from $33.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, April 11th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $32.00 price objective on shares of Paratek Pharmaceuticals in a report on Monday, April 24th. BidaskClub downgraded shares of Paratek Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, July 24th. Finally, Raymond James Financial, Inc. initiated coverage on shares of Paratek Pharmaceuticals in a report on Thursday, May 18th. They issued a “strong-buy” rating and a $36.00 price objective on the stock. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $37.44.
Shares of Paratek Pharmaceuticals (PRTK) traded up 10.51% during mid-day trading on Monday, reaching $21.55. 892,819 shares of the company were exchanged. The stock’s market capitalization is $594.78 million. The stock has a 50 day moving average price of $22.99 and a 200-day moving average price of $19.72. Paratek Pharmaceuticals has a 12 month low of $9.80 and a 12 month high of $26.10.
Paratek Pharmaceuticals (NASDAQ:PRTK) last posted its quarterly earnings data on Wednesday, August 2nd. The specialty pharmaceutical company reported ($0.64) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.25. The firm had revenue of $7.51 million during the quarter, compared to analysts’ expectations of $7.50 million.
In related news, COO Evan Loh sold 4,351 shares of Paratek Pharmaceuticals stock in a transaction on Wednesday, July 5th. The shares were sold at an average price of $23.58, for a total value of $102,596.58. Following the transaction, the chief operating officer now directly owns 112,783 shares in the company, valued at approximately $2,659,423.14. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Adam Woodrow sold 3,800 shares of Paratek Pharmaceuticals stock in a transaction on Wednesday, July 5th. The shares were sold at an average price of $23.58, for a total transaction of $89,604.00. Following the completion of the transaction, the vice president now owns 69,500 shares in the company, valued at $1,638,810. The disclosure for this sale can be found here. Over the last quarter, insiders sold 21,960 shares of company stock worth $524,342. 4.90% of the stock is currently owned by insiders.
Paratek Pharmaceuticals Company Profile
Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.
Receive News & Ratings for Paratek Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
